<DOC>
	<DOC>NCT00598208</DOC>
	<brief_summary>The primary objective of this trial is to investigate the dose -response relationship of a single injection of Org 38286 to initiate multifollicular growth for the first seven days in a controlled ovarian hyperstimulation (COH) protocol for IVF or ICSI.</brief_summary>
	<brief_title>A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Females of couples with an indication for COH and IVF or ICSI; &gt;=18 and &lt;=39 years of age at the time of signing informed consent; BMI &gt;=18 and &lt;=29 kg/m^2; Normal menstrual cycle length: 2435 days; Ejaculatory sperm (use of donated and/or frozen sperm is allowed); Willing and able to sign informed consent. History of/or any current (treated) endocrine abnormality; History of ovarian hyperstimulation syndrome (OHSS); History of/or current polycystic ovary syndrome (PCOS) or current polycystic ovaries according to USS (at least 10 follicles of 28 mm in each ovary); More than three unsuccessful COH cycles since the last established ongoing pregnancy (if applicable); History of non or low ovarian response to FSH/hMG treatment; Any clinically relevant hormone value outside the reference range during the early follicular phase (menstrual cycle day 27) as measured by the local laboratory (FSH, LH, E2, P, total T, TSH and prolactin): Any clinically relevant abnormal laboratory value; Less than 2 ovaries; Any ovarian and/or abdominal abnormality interfering with ultrasound examination; Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts); Epilepsy, diabetes, cardiovascular, gastrointestinal, hepatic, renal, pulmonary, or abdominal disease; History of presence of alcohol or drug abuse within 12 months prior to signing informed consent; Previous use of Org 36286; Use of hormonal preparations within 1 month prior to randomization; Hypersensitivity to Org 32489 (Puregon®) and/or Org 37462 (Orgalutran®) and/or Pregnyl® or any of their components; Administration of investigational drugs within three months prior to signing informed consent.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>In-vitro fertilization</keyword>
</DOC>